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Background and aims: Although the beneficial effects of statins on stroke have been widely 
demonstrated both in experimental studies and in clinical trials, the aim of this study is to prepare 
and characterize a new liposomal delivery system that encapsulates simvastatin to improve its 
delivery into the brain.
Materials and methods: In order to select the optimal liposome lipid composition with the 
highest capacity to reach the brain, male Wistar rats were submitted to sham or transitory middle 
cerebral arterial occlusion (MCAOt) surgery and treated (intravenous [IV]) with fluorescent-
labeled liposomes with different net surface charges. Ninety minutes after the administration of 
liposomes, the brain, blood, liver, lungs, spleen, and kidneys were evaluated ex vivo using the 
Xenogen IVIS® Spectrum imaging system to detect the load of fluorescent liposomes. In a second 
substudy, simvastatin was assessed upon reaching the brain, comparing free and encapsulated 
simvastatin (IV) administration. For this purpose, simvastatin levels in brain homogenates from 
sham or MCAOt rats at 2 hours or 4 hours after receiving the treatment were detected through 
ultra-high-protein liquid chromatography.
Results: Whereas positively charged liposomes were not detected in brain or plasma 90 minutes 
after their administration, neutral and negatively charged liposomes were able to reach the brain 
and accumulate specifically in the infarcted area. Moreover, neutral liposomes exhibited higher 
bioavailability in plasma 4 hours after being administered. The detection of simvastatin by 
ultra-high-protein liquid chromatography confirmed its ability to cross the blood–brain barrier, 
when administered either as a free drug or encapsulated into liposomes.
Conclusion: This study confirms that liposome charge is critical to promote its accumulation 
in the brain infarct after MCAOt. Furthermore, simvastatin can be delivered after being encap-
sulated. Thus, simvastatin encapsulation might be a promising strategy to ensure that the drug 
reaches the brain, while increasing its bioavailability and reducing possible side effects.
Keywords: simvastatin, liposomes, delivery, brain, stroke, rat
Introduction
Despite all efforts of neuroscience community, stroke still remains a major cause of death 
and disability worldwide that contributes to the rising costs of health care.1 Nowadays, 
thrombolytic treatment with the tissue plasminogen activator agent is the only existing 
pharmacological therapy for the acute phase of stroke.2 Thus, the need to find efficient 
neuroprotectant drugs with minimal side effects is becoming an urgency.
Many studies have shown the beneficial effects of simvastatin statin known as 
3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors when administered 
before or after ischemic stroke in animals as well as in decreasing the incidence of stroke 
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in patients.3–6 The benefits of statins in cerebral ischemia have 
not been attributed to their cholesterol-lowering therapeutic 
actions. Alternatively, pleiotropic effects seem to be impli-
cated in their protective role in stroke.7,8 Nevertheless, high-
dose statin-based therapy in humans has been associated with 
infrequent but undesirable side effects such as myopathy, 
rhabdomyolysis, and elevated hepatic transaminases.9 In this 
sense, the use of drug delivery systems such as liposomes is 
being seriously considered in order to reduce the side effects 
by site-selected delivery of the drug.10 In spite of simvastatin 
being able to cross the blood–brain barrier (BBB) per se 
due to its lipophilic condition and its molecular weight 
(418 kDa), it exhibits poor bioavailability.11 Furthermore, 
it has been reported that BBB disruption occurs at an early 
stage after cerebral occlusion, allowing macromolecules to 
pass through the spaces between capillary endothelial cells.12 
Accordingly, nanoparticles might also be able to leak into 
brain parenchyma during the acute phase of cerebral isch-
emia. Interestingly, Sahagun et al13 suggested that both size 
and charge of drug carriers are important in determining net 
brain permeation.
Here, our hypothesis is that the bioavailability of simvas-
tatin can be enhanced when it is encapsulated into liposomes, 
optimizing the opportunities to reach the ischemic brain 
and increasing the neuroprotective effect, while making 
the drug safer. To this end, in this study, we explored and 
characterized the tissue internalization patterns of liposomes 
presenting different net surface charges. From this study, we 
assessed how simvastatin encapsulated into neutral liposomes 
is the best candidate to reach the rat ischemic brain compared 
to the administration of the free drug.
Materials and methods
ethics statement
All procedures were approved by the Ethics Committee for 
Animal Experimentation of the Vall d’Hebron Research 
Institute (protocol numbers 01/13 and 58/13) and conducted 
in compliance with the Spanish legislation and in accordance 
with the Directives of the European Union. In all experi-
ments, male Wistar rats (270–300 g; Charles River Labora-
tories Inc., Wilmington, MA, USA) were used. Rats were 
kept in a climate-controlled environment on a 12-hour light/ 
12-hour dark cycle. Food and water were available ad libitum, 
and analgesia (buprenorphine 0.05 mg/kg subcutaneous (sc); 
Divasa Farma-Vic S.A., Barcelona, Spain) was given to all 
rats before starting the surgical procedure to minimize their 
pain and discomfort.
Intraluminal transitory middle cerebral 
arterial occlusion
Regional cerebral blood flow was monitored during the sur-
gery with a laser Doppler probe (Moor Instruments, Devon, 
UK), and to that end, cranial trepanation was performed 
the day before middle cerebral arterial occlusion (MCAO) 
surgery. In summary, animals under isoflurane (Abbott 
Laboratories, Abbott Park, IL, USA) effects were placed in 
a stereotactic table, and using a drill of 1 mm in diameter, 
a hole was made in the skull, above the region irrigated by 
middle cerebral artery (MCA).14
Infarction in the territory of the MCA was induced 
by introducing an intraluminal filament, as described 
previously.14 Animals were anesthetized under spontaneous 
respiration with isoflurane in oxygen during surgery, and 
body temperature was maintained at 37°C using a heating pad 
connected to a rectal probe. In brief, after surgical exposure 
of the bifurcation of the external carotid artery and the inter-
nal carotid artery on the right side, a silicone-coated nylon 
monofilament (Doccol Corporation, Sharon, MA, USA, 
reference number: 403723PK10) was introduced to occlude 
the MCA. After occlusion, animals were allowed to recover 
from anesthesia. Reperfusion was induced 90 minutes later, 
and to this end, animals were re-anesthetized.
Only animals that exhibited a reduction of .75% in 
regional cerebral blood flow after filament placement and a 
recovery of .75% after filament removal were included in 
the study. Sham-operated rats were submitted to the same 
experimental surgery without filament insertion, whereas 
naïve rats did not receive any surgical procedure. Analgesia 
was administered just after cranial trepanation and also after 
MCAO or sham surgery.
experimental design
A total of 103 animals were needed to complete the study; 
45 animals were used to characterize different liposome 
lipid compositions and 58 were used to evaluate brain 
simvastatin distribution through ultra-high-protein liquid 
chromatography (UHPLC). A flow chart has been designed 
in order to justify the excluded animals and the criteria 
established (Figure 1).
Neurological evaluation
Rats were assessed using a nine-point neurological deficit 
scale (modified Bederson test), as previously described.15 
Four consecutive tests were conducted: 1) spontaneous activ-
ity (moving and exploring =0, moving without exploring =1, 
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no moving or moving only when pulled by the tail =2); 2) 
left drifting during displacement (none =0, drifting only when 
elevated by the tail and pushed or pulled =1, spontaneous 
drifting =2, circling without displacement or spinning =3); 
3) parachute reflex (symmetrical =0, asymmetrical =1, 
contralateral [CL] forelimb retracted =2); and 4) resistance to 
left forepaw stretching (stretching not allowed =0, stretching 
allowed after some attempts =1, no resistance =2). 
Neurological score was assessed in a blinded manner at 
90 minutes. Scores .3 enabled us to ensure that animals 
were infarcted.
simvastatin activation
In all experiments, simvastatin was used in its activated form. 
Simvastatin is a lactone prodrug that is activated by opening 
the lactone ring to its β-hydroxy acid form by hydrolysis 
in a strong alkaline medium.16 For activation, simvastatin 
was first dissolved in vehicle (distilled H
2
O [75%], absolute 
ethanol [10%], and 0.1 M NaOH [15%]). Then, the solution 
was incubated at 50°C for 2 hours adjusting the pH at 7.2. 
To verify the activation of simvastatin, Fourier transform 
infrared spectroscopy analysis was used. In this study, we 
focused on examining the frequency range from 3,000 cm−1 
to 3,700 cm−1 to verify the formation of multiple hydroxyl 
groups in the active simvastatin form.
liposome formulation and 
characterization
1,2-Didodecanoyl-sn-glycero-3-phosphocholine (DLPC) 
was purchased from Lipoid, Steinhausen, Switzerland. 
Cholesterol, cholesteryl–polyethylene glycol 600 sebacate 
(CHOL–PEG), and 1,2-dioleoyl-sn-glycero-3-phosphoric 
acid monosodium salt (DOPA−) were purchased from 
Sigma Aldrich Co. (St Louis, MO, USA). Cholesteryl 3β-N-
(dimethylaminoethyl) carbamate hydrochloride (CHOL+) 
and 1,2-dioleoyl-sn-glycero-3-phosphoethanolamine 
(DOPE) were supplied by Avanti Polar Lipids (Alabaster, 
AL, USA). Alexa Fluor 750 (AF750) in its succinimidyl 
ester form was purchased from Thermo Fisher Scientific 
(Waltham, MA, USA).
Differently charged liposomes (positive, negative, and 
neutral) were prepared using the thin film hydration method 
with some modifications.17,18 Briefly, DLPC, CHOL, CHOL+, 
CHOL–PEG, and DOPA were dissolved in chloroform solu-
tions (100 mg/mL) and mixed at the desired molar ratios 
under sterile conditions (Table 1). The final concentration 
Figure 1 Diagram summarizing the number of animals included (Incl) and excluded (excl) per substudy.
Abbreviations: McaO, middle cerebral arterial occlusion; h, hours.
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of lipid was 28 mM. The organic solvent was then evapo-
rated under vacuum and nitrogen to obtain a dry lipid film. 
Afterward, the film was hydrated with the appropriate buffer 
(phosphate-buffered saline or 6 mg/mL solution of active 
simvastatin in water). The resulting lipid suspension was 
then vigorously shaken, and the liposomes obtained were 
homogenized by means of an extruder (Lipex Biomembranes, 
Vancouver, BC, Canada) through a polycarbonate mem-
brane (200 nm pore size) to finally obtain small unilamellar 
vesicles (SUVs).
Simvastatin encapsulation efficiency was calculated 
according to the equation EE (%) = [(C
total
 − C
free
)/C
total
] ×100, 
where C
total
 is the initial simvastatin concentration and C
free
 
is the concentration of nonencapsulated simvastatin. To 
quantify C
free
, liposomes were centrifuged and aliquots of 
supernatant were analyzed by UV–vis spectroscopy using 
a Nanodrop ND-1000 (Thermo Fisher Scientific). Mean 
absorbance values were introduced in a standard calibra-
tion curve for the estimation of C
free
 simvastatin. Liposome 
integrity was checked by dynamic light scattering and cryo-
genic transmission electron microscopy (JEOL-JEM 1400 
microscope; JEOL, Tokyo, Japan). Particle size distributions 
by dynamic light scattering and the superficial charge of 
liposomes – expressed as zeta potential (ζ) – were measured 
using Malvern Zetasizer (Malvern Instruments, Malvern, 
UK) in undiluted samples. The value of zeta potential of 
simvastatin-loaded liposomes was measured after removing 
the nonencapsulated simvastatin from preparations by ultra-
centrifugation at 110,000× g for 30 minutes at 10°C.
liposome biodistribution
To monitor distribution in the rat body, liposomes were 
fluorescently labeled with AF750 (catalog no: A-20011; 
Thermo Fisher Scientific). To this end, AF750 succin-
imidyl ester and DOPE-NH
2
 were conjugated as previously 
described.19 Only conjugated AF750 was detected by thin-
layer chromatography (R
f
 =0.6), indicating that conjugation 
was complete. The fluorescent-labeled AF750 liposomes 
were prepared by incorporating AF750-DOPE into the lipid 
mixture (0.38 mM).
One milliliter of AF-labeled liposomes (neutral, posi-
tively, or negatively charged) was intravenously injected 
into MCAO (n=3–4 per liposome charge) or sham (n=3–4 
per group) rats 90 minutes after ischemia induction and sham 
surgery, respectively. In MCAO animals, the filament was 
also removed after 90 minutes of occlusion. Thus, labeled 
liposomes were administered in ischemic rats just when the 
reperfusion started. All rats were euthanized 90 minutes after 
liposome administration, and the brain, liver, spleen, kidneys, 
lungs, and plasma were obtained from all animals. All organs 
were entirely maintained on ice until ex vivo analysis with 
an imaging system (Xenogen IVIS® Spectrum; PerkinElmer 
Inc., Waltham, MA, USA, located at the Molecular Imaging 
Platform [PIM] of the CIBER-BBN-VHIR In Vivo Experi-
mental Platform). Brains were analyzed considering both 
as the entire organ and after slicing them into 2 mm thick 
coronal sections in order to explore the exact location of the 
liposomes. Captured images were then analyzed using the 
Living Image 4.3.1 software (PerkinElmer Inc.). Liposome 
signal data were in all cases corrected by subtracting 
the signal detected in animals free of liposome administration 
(background). Fluorescent signal data from all tissues were 
obtained considering the mean value between the anterior 
and the posterior view. All data obtained by Xenogen IVIS® 
Spectrum experiments are expressed as radiant efficiency, 
considered a calibrated measurement of the photon emis-
sion from the subject and technically defined as fluores-
cence emission radiance per incident excitation intensity: 
photons/s/cm2/sr (steradian)/µW/cm2.
liposome kinetics in plasma
Naïve rats intravenously received 1 mL of AF-labeled lipo-
somes neutral or negatively charged (n=3, respectively), 
whereas positively charged liposomes were discarded in this 
experiment due to the lack of results obtained in the previous 
ones. Blood samples were collected from the tail vein after 
1.5 hours, 4 hours, or 24 hours of liposomes administration 
and stored in ethylenediaminetetraacetic acid tubes. After-
ward, 50 µL of plasma was placed in 96-well plates and 
analyzed with the Xenogen IVIS® Spectrum. The fluorescent 
Table 1 liposome composition and characterization
Sample Liposome lipid composition Encapsulated ζ potential (mV) Mean size (nm) PDI
lIP1+ DlPc 50%/chOl 10%/chOl–Peg 5%/chOl (+) 35% PBs +30.17 157.57 0.12
lIP2= DlPc 50%/chOl 45%/chOl–Peg 5% PBs +2.21 171.07 0.10
lIP3− DlPc 50%/chOl 45%/chOl–Peg 5%/DOPa (−) 35% PBs −38.30 154.60 0.19
lIP4s DlPc 50%/chOl 45%/chOl–Peg 5% simvastatin 6 mg/ml −1.01 151.85 0.15
Abbreviations: PDI, polydispersity index; DlPc, 1,2-didodecanoyl-sn-glycero-3-phosphocholine; chOl, cholesterol; chOl–Peg, cholesteryl–polyethylene glycol 600 
sebacate; PBs, phosphate-buffered saline; DOPa, 1,2-dioleoyl-sn-glycero-3-phosphoric acid monosodium salt.
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signal was quantified with the Living Image software, and 
the results were expressed as radiant efficiency.
Determination of simvastatin in brain 
tissue (UhPlc)
The aim of this substudy was to explore the ability of simvastatin 
to cross the BBB and assess its possible increased accumula-
tion after its encapsulation into liposomes. Sham or MCAO 
rats were given 1 mL of simvastatin through the tail vein, 
either free or encapsulated into neutral liposomes (previ-
ously chosen in the former substudy), and euthanized at 
2 hours (n=16) or 4 hours (n=16) after intravenous (IV) 
drug administration. Naïve animals (n=4 in each group time) 
without receiving treatment were also evaluated to correct the 
background signal. Briefly, under anesthesia, animals were 
transcardially perfused with a heparin solution in saline fol-
lowed by pure saline solution, both injected with an infusion 
pump. Perfusion took 20 minutes and ensured a complete 
removal of both cerebral blood and circulating simvastatin. 
Then, brains were removed, divided into ipsilateral (IP) and 
CL hemispheres, and weighed. Each hemisphere was homo-
genated separately with a buffer composed of methanol and 
distilled water (1:1 volume, 5 mL/g of tissue) and sonicated. 
Homogenate supernatants were stored at −80°C until the 
analysis was performed in all samples at once.
Simvastatin extraction was performed as previously 
described.20 One hundred microliters of each sample of brain 
homogenate was mixed with 100 µL of internal standard 
(IS) solution ([2H
6
]-simvastatin hydroxy acid ammonium 
salt, catalog no: c3520; Alsachim, Illkirch-Graffenstaden, 
France), which was used to correct simvastatin quantification, 
and 150 µL of acetonitrile. Then, the mixture was vortexed 
at 153× g for 30 seconds, and 50 µL of 5 M ammonium 
formate buffer (pH 4) was added. Samples were vortexed 
again and centrifuged at 13,000× g at 4°C for 10 minutes. 
One hundred microliters of supernatant was transferred into 
the injection tube, and the resulting mixture was diluted 
with 100 µL of mobile phase (0.5 mM pH 4.5 ammonium 
acetate:acetonitrile) (70:30). Tubes were vortexed one more 
time before the samples were injected.
Chromatographic detection was performed using an 
Acquity UPLC® System (Waters Corporation, Milford, 
MA, USA) (High Technology Unit [UAT]), with ACQ-
binary solvent manager and CQ-sample manager. Separa-
tion was done in an ACQUITY BEH 2.1×100 mm phenyl 
analytical column with precolumn filter. The mobile phase 
was composed of a mixture of acetonitrile and 0.5 mM 
ammonium acetate buffer pH 4.5 (30:70) using a gradient 
elution. Within 1.5 minutes, the concentration was changed to 
30% of ammonium acetate buffer and subsequently to 5% of 
the buffer within 5.25 minutes. Flow rate was 0.25 mL/min. 
The analytical column was kept at 35°C by column oven, and 
the solutions were stored in the autosampler at 4°C. The full 
loop injection mode was set up to inject 5 µL using a 10 µL 
injection loop. Acetonitrile was used as the strong wash 
solvent, and 70% ammonium acetate buffer in acetonitrile 
was used as the weak wash solvent.
Final detection was performed by a tandem mass spec-
trometry (MS/MS) triple quadrupole system Xevo TQ MS 
(Waters Corporation) with electrospray ionization in nega-
tive mode for simvastatin acid and simvastatin acid-d
6
 (IS) 
and in positive mode for simvastatin, using the following 
transitions: 1) m/z =435 to 114.7 and 318 for simvastatin 
acid, 2) m/z =441 to 319.9 for IS, and 3) m/z =419 to 199 for 
simvastatin. The range of simvastatin acid quantification was 
from 4 ng/mL to 40 ng/mL in brain homogenate.
statistical analysis
Data were analyzed using the GraphPad Prism_v5 software 
(GraphPad Software, Inc., La Jolla, CA, USA). Statistical 
significance for intergroup differences was tested by the 
Student’s t-test or the analysis of variance followed by the 
Bonferroni post hoc test for parametric data. For nonpara-
metric data, the Mann–Whitney or Kruskal–Wallis test fol-
lowed by Dunn’s multiple comparison was performed. For 
parametric data, bars or symbols represent mean ± SD, and 
box plots or symbols represent median (interquartile range) 
for nonparametric data. Two-way analysis of variance was 
used to compare the liposome signal in plasma over time. 
A P-value ,0.05 was considered statistically significant at 
a 95% confidence level.
Results
liposome characterization
Series of liposomal formulations with different lipid mem-
brane compositions and net surface charges were initially 
prepared to determine the best formulation that allows an 
optimal permeation to the ischemic brain. Table 1 summa-
rizes the characteristics of all liposomes used in this study. 
Three lipid mixtures were studied: 1) LIP1+, consisting of the 
cationic lipid mixture DLPC/CHOL/CHOL–PEG/CHOL (+); 
2) LIP2=, formed by the neutral mixture DLPC/CHOL/
CHOL–PEG; and 3) LIP3−, formed by the anionic lipid mix-
ture DLPC/CHOL/CHOL–PEG/DOPA (−) (Figure 2A–C). 
In all cases, 5% of CHOL–PEG was used as PEGylating 
agent to yield stealth vesicles, and fluorescent AF750 dye was 
added to the lipid mixture to obtain fluorescent-labeled lipo-
somes for its in vivo tracking.21 All formulations consisted 
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of small multivesicular vesicles (SUVs) with a mean particle 
size ranging from 154.60 nm to 171.07 nm.
cerebral distribution of liposomes
AF750-labeled liposomes were detected in the whole brain 
90 minutes after their administration both in sham and in 
MCAO animals only when liposomes had neutral or nega-
tive zeta potential (Figure 3). A significant signal increase 
in brain from sham animals was observed only when neutral 
liposomes administration was compared with the positive 
ones (neutral: 3.825e+008 [2.960e+008, 6.150e+008] vs posi-
tive: 3.860e+007 [0.0, 7.510e+007], P,0.05) (Figure 3C). 
Negative liposomes also showed a higher signal than posi-
tive ones (negative: 3.05e+008 [2.11e+008, 3.25e+008]), 
although nonsignificantly. In these brains, neutral and 
negative liposome fluorescence was associated with areas of 
high vascular density corresponding with the zone of venous 
sinuses confluence (Figure 3A).
In accordance, ischemic rats administered with neutral 
liposomes also presented a significant signal increase in 
Figure 2 cryoTeM images of liposomes formed by the lipid mixtures.
Notes: (A) DlPc/chOl/chOl–Peg/chOl (+), (B) DlPc/chOl/chOl–Peg (=), and (C) DlPc/chOl/chOl–Peg/DOPa (−). scale bar: 200 nm.
Abbreviations: cryoTeM, cryogenic transmission electron microscopy; DlPc, 1,2-didodecanoyl-sn-glycero-3-phosphocholine; chOl, cholesterol; chOl–Peg, cholesteryl–
polyethylene glycol 600 sebacate; DOPa, 1,2-dioleoyl-sn-glycero-3-phosphoric acid monosodium salt.
Figure 3 Representative ex vivo rat brain images and fluorescent signal quantifications captured by an imaging system (Xenogen IVIS® spectrum).
Notes: (A) Whole brain of representative sham and infarcted ischemia rats receiving different net surface charged liposomes. (B) representative sliced rat brain after being 
submitted to an McaO and receiving neutral liposomes. Fluorescent signal colocalized with infarcted area. (C) Quantifications of liposome-emitted signal in sham and MCAO 
rat brain expressed as radiant efficiency. Images are adjusted to the scale positioned beside. Data present four independent experiments in which three to four animals per 
group were included. Median values (interquartile range) are represented and significant differences are indicated as *P,0.05.
Abbreviations: lIP1+, positive liposomes; lIP2=, neutral liposomes; lIP3−, negative liposomes. McaO, middle cerebral arterial occlusion; p, photons; sec, seconds; sr, steradian.
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the brain only when compared with the signal after the 
administration of positive liposomes (neutral: 1.320e+009 
[3.040e+008, 2.490e+009] vs positive: 3.430e+007 
[5.550e+006, 7.890e+007], P,0.05) (Figure 3C). Again, 
negative liposomes presented a higher signal than the positive 
ones but without reaching statistical significance (negative: 
1.78e+008 [1.78e+008, 1.10e+009]). Similar quantifications 
were obtained when brains were sliced into coronal sections 
(data not shown). Remarkably, when liposomes (neutral or 
negatively charged) were administered in ischemic animals, 
signal tended to concentrate in the ischemic hemisphere, 
mostly in the infarcted region, rather than on the CL side. 
Ischemic region is observed as a pale area in nonfluorescent 
brain slices, and it is also known considering the patterns of 
the animal model used (Figure 3B).22
liposome distribution in other tissues
Ninety minutes after liposome administration, different 
organs were analyzed by Xenogen IVIS® Spectrum to explore 
liposome affinity to different tissues depending on their net 
surface charge. Liver, spleen, kidneys, and lungs were exam-
ined in sham (n=11) and ischemic animals (n=10) (Figure 4). 
Our results show that only sham rats treated with positive 
liposomes presented a significant accumulation in the liver 
compared to the neutral and negative liposomes (positive: 
2.012e+011±2.120e+010 vs neutral: 1.393e+011±2.319e+010, 
P,0.05 vs negative: 1.267e+011±2.173e+010, P,0.01) 
(Figure 4A). Likewise, only sham rats treated with positive lipo-
somes presented a higher signal in lungs compared to neutral 
liposomes (positive: 7.230e+009 [6.750e+009, 5.480e+010] 
vs neutral: 2.865e+009 [5.670e+008, 3.970e+009], P,0.05), 
while the comparison with negative liposomes did not reach 
statistical significance (negative: 3.18e+009 [2.44e+009, 
3.6e+009]; Figure 4D). Nonsignificant differences were 
observed for the differently charged liposomes when spleen 
and kidneys were evaluated (Figure 4B and C). No comparison 
among ischemic groups presented significant differences.
liposome bioavailability in plasma
Plasma collected 90 minutes after liposome administration 
exhibited unexpected differences between liposome-charged 
groups. Sham animals showed a significant longer blood 
circulation time of neutral liposomes compared with the posi-
tive ones (neutral: 6.445e+007 [4.960e+007, 6.900e+007] 
Figure 4 Fluorescent signal quantifications of images captured by Imaging system (Xenogen IVIS® spectrum) considering distribution of differentially charged liposomes within 
the body in sham and McaO rats.
Notes: liposome accumulation in (A) liver, (B) spleen, (C) kidneys, and (D) lungs. In each group, three to four animals were included. Mean ± sD  or median values 
(interquartile range) are represented depending on normality data distribution and significant differences are indicated as *P,0.05, **P,0.01.
Abbreviations: +, positive; =, neutral; −, negative; McaO, middle cerebral arterial occlusion; sD, standard deviation.
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vs positive: 2.115e+006 [480,000, 4.840e+006], P,0.05). 
Likewise, ischemic rats treated with neutral liposomes 
showed a significant higher fluorescent signal in plasma 
compared to animals treated with positive liposomes 
(neutral: 1.100e+008 [5.210e+007, 1.250e+008] vs positive: 
3.995e+006 [1.840e+006, 6.020e+006], P,0.05) (Figure 5A 
and B). Here, although fluorescent signal emitted by neutral 
liposomes was higher than that emitted by negative lipo-
somes in both sham and ischemic animals, differences did 
not reach statistical significance (sham negative: 4.15e+007 
[1.810e+007, 6.270e+007]; ischemic negative: 2.240e+007 
[1.830e+007, 2.840e+007]).
To further study the consequences of administering 
neutral or negatively charged liposomes, the plasma bio-
availability of these two groups was examined in greater 
detail at different time points. Strikingly, 90 minutes 
after administration, neutral liposomes exhibited a sig-
nificantly elevated signal compared to negative lipo-
somes (neutral: 1.437e+008±8.737e+006 vs negative: 
6.353e+007±9.278e+006, P,0.001). Similarly, the signal 
detected for neutral liposomes was also higher 4 hours 
after administration (neutral: 3.767e+007±1.386e+007 vs 
negative: 1.470e+007±4.987e+006, P,0.05), whereas hardly 
any signal was observed at 24 hours in any of the groups 
(Figure 5C and D).
simvastatin detection in the brain
Considering the results of our first substudy, neutral lipo-
somes were selected as the proper candidates for brain 
delivery. Consequently, in order to study simvastatin arrival 
into the brain, neutral liposomes were characterized after 
being loaded with the drug (LIP4S) (Figure 6A). When 
loaded with simvastatin, neutral liposomes showed a mean 
diameter of 151.85 nm (polydispersity index =0.15) and a 
neutral surface charge of −1.01 mV. The encapsulation effi-
ciency of simvastatin by liposomes was 64.37%±7.55%. By 
cryogenic transmission electron microscopy analysis, it was 
also observed that liposomes incorporating the simvastatin 
still presented the characteristic small multivesicular vesicles 
(SUV) morphology (Figure 6B).
Here, it is important to mention that by analyzing brain 
hemisphere homogenates by UHPLC technique, we were 
able to detect both simvastatin forms (active and inactive), 
although simvastatin administered to animals was entirely 
Figure 5 Presence of liposomes in plasma.
Notes: (A) Plasma collected from sham or ischemic rats 90 minutes after receiving liposomes. Median values (interquartile range) are represented and significant differences 
are indicated as *P,0.05. (B) representative plasma image of one experiment. (C) liposome kinetics in plasma. Blood was collected from naïve rats (with no surgical 
procedure) after 1.5 hours, 4 hours, and 24 hours of receiving neutral or negatively charged liposomes. symbols indicated mean ± sD. (D) Image representing data on graph 
(C). Images are adjusted to the scale positioned beside. In all experiments, three to four animals per group were considered. Significant differences are represented as 
*P,0.05, and ***P,0.001.
Abbreviations: +, positive; =, neutral; −, negative; McaO, middle cerebral arterial occlusion; h, hours; p, photons; sec, seconds; sr, steradian; sD, standard deviation.
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activated following the aforementioned protocol (“Liposome 
formulation and characterization” section).
An IS consisting in simvastatin hydroxy acid ammonium 
salt was used to correct simvastatin quantification. As shown 
in Figure 6C–E, the three peaks corresponding to active 
simvastatin, IS, and inactive simvastatin, respectively, were 
easily distinguishable. The three peaks were observed in all 
analyzed samples.
Through UHPLC technique, we were able to demon-
strate that free active simvastatin was able to cross the BBB 
(Figure 7A), as it was detectable in rat brains 2 hours after admin-
istration. In general terms, higher active simvastatin levels were 
detected when rats were euthanized at 2 hours compared with 
4 hours posttreatment. This difference was clearly evidenced 
when active simvastatin levels were compared between IP isch-
emic groups (IP ischemic [isch] 2 hours: 2.6 [2.3, 3.8] vs IP isch 
4 hours: 0.85 [0.3, 1.4], P,0.05). Interestingly, ischemic brains 
showed higher simvastatin accumulation in the IP hemisphere 
than in the CL hemisphere (2 hours: IP isch: 2.6 [2.3, 3.8] vs 
CL isch: 1.8 [0.0, 2.4], P,0.05), whereas no differences were 
detected between hemispheres in brains from sham animals.
Concerning the detection of free simvastatin in its inac-
tive form (Figure 7B), higher amounts were also obtained 
after 2 hours compared to 4 hours in the ischemic groups 
(IP isch 2 hours: 81 [66, 88] vs IP isch 4 hours: 9.6 [4.8, 
17.30], P,0.05; and CL isch 2 hours: 77.10 [75.50, 85.70] 
vs CL isch 4 hours: 7.6 [4.7, 13.30], P,0.05). Contrarily, no 
differences were found between inactive simvastatin in the 
ischemic areas compared to the CL or sham brains.
We then focused on the comparison between simvastatin 
levels in the rat brain when it was intravenously administered 
encapsulated into liposomes or as a free drug. Regarding 
detection of the active form (Figure 7C), we observed higher 
levels when it was encapsulated compared with the free form 
in sham animals, although the difference was significant 
only at 4 hours post administration (sham free 4 hours: 0.35 
[0.3, 0.4] vs sham liposomes (lipos) 4 hours: 0.65 [0.6, 0.9], 
P,0.05). In contrast, no differences were observed when 
comparing free and encapsulated administration in ischemic 
animals at any of the evaluated times (isch free 2 hours: 2.6 
[2.3, 4.7] vs isch lipos 2 hours: 3.35 [1.3, 2.4] and isch free 
4 hours: 0.85 [0.3, 1.4] vs isch lipos 4 hours: 0.9 [0.5, 1]).
Figure 6 simvastatin-loaded liposome characterization.
Notes: (A) structure and composition of neutral liposome compounds used in detection experiments. (B) cryoTeM image of liposomes with simvastatin encapsulated 
formed by the lipid mixture DlPc/chOl/chOl–Peg (scale bar: 200 nm). (C–E) UHPLC chromatographic profile of peaks corresponding to (C) active simvastatin (also 
named acid simvastatin), (D) Is (simvastatin hydroxy acid ammonium salt), and (E) inactive simvastatin (also named lactone). For each compound analyzed, retention time 
(expressed in minutes) and transition are presented.
Abbreviations: cryoTeM, cryogenic transmission electron microscopy; DlPc, 1,2-didodecanoyl-sn-glycero-3-phosphocholine; chOl, cholesterol; chOl–Peg, 
cholesteryl–polyethylene glycol 600 sebacate; UHPLC, ultra-high-protein liquid chromatography; IS, internal standard; DOPE, 1,2-dioleoyl-sn-glycero-3-phosphoethanolamine; 
simv, simvastatin; min, minute; Peg, polyethylene glycol.
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Finally, we evidenced that simvastatin levels in the 
nonactive form were almost negligible when the drug was 
encapsulated into liposomes (Figure 7D). Thus, ischemic 
rats treated with the free form presented significantly higher 
brain retention of inactive simvastatin at both 2 hours and 
4 hours than when it was previously encapsulated (isch free 
2 hours: 81.40 [66.0, 88.20] vs isch lipos 2 hours: 7.95 [0.2, 
12.40], P,0.05, and isch free 4 hours: 9.65 [4.8, 17.30] vs 
isch lipos 4 hours: 1.2 [0.9, 1.4], P,0.05).
Discussion
As previously described, the use of a liposomal drug deliv-
ery system is a promising strategy to avoid side effects and 
enhance drug efficiency by changing the distribution of the 
intact drug.12 Liposomes show several advantages, such as 
biocompatibility or nontoxicity, ability to protect their cargo 
from degradation by plasma enzymes, and the capacity to 
transport their load across biological membranes.23 To date, 
liposomes have been used clinically as delivery systems 
for therapeutic chemotherapeutic agents, antibiotics, and 
antifungals showing an increase in the safety and efficacy 
of some drugs.24 Taking into account the difficulty for neu-
roprotectants to reach the target zone due to the BBB char-
acteristics, we considered that the development of a suitable 
liposomal carrier to encapsulate neuroactive compounds was 
highly encouraging.
?????????????? ????????
??????????? ?????????????????????????????????? ?????????????????????????
???????????????? ????????
? ???
??
??
??
??
?
???
??
??
??
??
?
?? ??
????
??? ??? ??? ???
??? ?????? ??? ???????????????????? ????????
?? ??
????
?? ?? ?? ???? ?? ?? ??
????
???? ????? ???? ????? ???? ????? ???? ????? ????? ???? ????? ???? ????? ???? ?????
???????? ???????? ????????
?? ?? ?? ??
?
?
?
?
?
?
?
??
?
?
?
?
?
?
?
?
?
?
??
????
????
????
???
????
???
???
????
????
???
????
????
?
???
????
????
???
????
????
?
???
????
????
???
????
????
?
????
? ?
? ?
Figure 7 Simvastatin detection in brain tissue through UHPLC technique after intravenous administration of 1 mL of free simvastatin or simvastatin encapsulated into neutral 
liposomes.
Notes: all rats were treated with the same simvastatin dose (20 mg/kg). rats were submitted to sham or McaO surgery, treated 90 minutes later, and killed 2 hours or 
4 hours after treatment administration. (A) Detection of simvastatin in its active form when rats were treated with free simvastatin and euthanized 2 hours or 4 hours later. 
(B) Detection of simvastatin in its lactone form (inactive) when rats were treated with free simvastatin and killed 2 hours or 4 hours later. (C) Detection of simvastatin 
in its active form in IP hemispheres when rats were treated with free or encapsulated simvastatin and killed 2 hours or 4 hours later. (D) Detection of simvastatin in its 
lactone form (inactive) in IP hemispheres when rats were treated with free or encapsulated simvastatin and killed 2 hours or 4 hours later. In all experiments, three to five 
animals per group were included. Box plots indicated median (interquartile range). After applying Mann–Whitney  test, significant differences are represented as *P,0.05 
for comparisons between sham and ischemic animals, #P,0.05 for comparisons between IP and cl hemispheres (a) and Free and lipos treatments (c, D) and †P,0.05 for 
comparisons between 2 hours and 4 hours. Broken lines represent background signal detected through UHPLC technique when brains of naïve animals without receiving 
treatment were analyzed.
Abbreviations: UHPLC, ultra-high-protein liquid chromatography; MCAO, middle cerebral arterial occlusion; IP, ipsilateral; CL, contralateral; IS, internal standard; simv, 
simvastatin; h, hours; Isch, ischemic; lipos, liposomes.
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Aggarwal et al25 previously stated that nanoparticle prop-
erties such as size, shape, solubility, surface modifications, 
and surface charge (zeta potential) can determine their distri-
bution within the body. For instance, the presence of PEG on 
the surface of liposomes has been shown to extend blood cir-
culation time while reducing mononuclear phagocyte system 
uptake and consequently decreasing their recognition by the 
liver and spleen.21,26 On the other hand, plasma proteins are 
described as binding the surface of nanoparticles immediately 
upon their introduction into a physiological environment, 
forming a nanoparticle–protein complex that affects the 
internalization process of nanoparticles into macrophages and 
their overall distribution throughout the body.25,27,28 Accord-
ingly, Gessner et al29 postulated plasma protein absorption as 
a key factor for the in vivo organ distribution of intravenously 
administered colloidal drug carriers and concluded that this 
biodistribution was strongly influenced by the surface char-
acteristics of nanoparticles.
In this study, we produced and characterized liposomes 
with different net surface charges to show how liposome 
surface charge helps to define their behavior and distribution, 
supporting the aforementioned hypothesis.
From our data, and in spite of the small sample size of the 
groups, we can conclude that positively charged liposomes 
present different behaviors in comparison to neutral or nega-
tively charged ones. Positive liposomes were not detectable in 
brain tissue, which was likely attributable to different factors. 
On one hand, they were also absent in plasma 90 minutes 
after administration, probably due to the high plasma protein 
absorption. Accordingly, Hernández-Caselles et al30 found 
a good correlation between the amounts of blood proteins 
absorbed by liposomes and their stability, the liposomes 
with the highest protein intake being the most unstable. 
Furthermore, in another study, cationic particles were found 
to strongly bind to human erythrocytes, and this fact was 
reported to lead to the impossibility of liposomes crossing 
the BBB in the presence of blood cells.31 On the other hand, 
we could detect positively charged liposomes significantly 
retained in lungs and liver compared with the other two 
liposomes. In this sense, retention of particles in the lungs 
consequently impedes their circulation in the blood stream, 
while Kupffer cells in the liver have been described as play-
ing an important role in also removing liposomes from the 
circulation, thus accelerating their elimination process.32
When we analyzed the liposome detection in brains from 
sham or ischemic rats, we observed that neutral and nega-
tive liposomes were able to cross the BBB, either when its 
permeability was altered (after MCAO) or when it remained 
intact (sham animals). Data from sham animals turned out to 
be quite homogenous, whereas higher intragroup variability 
was obtained among ischemic rats, probably attributable to 
the lesion severity.
Furthermore, we demonstrated that negative and neutral 
liposomes were prone to accumulate in the ischemic core of 
the brain. In this sense, we consider that the BBB disruption 
in this area, as well as the inflammatory processes around the 
ischemic lesion, is responsible for this interesting accumula-
tion, thus agreeing with the statement of Schroeder et al, who 
consider that the great interest in liposomal delivery systems 
stems from their ability to accumulate in sites of increased 
vascular permeability.33–36
From our results, we speculate that whereas in sham 
animals liposome–cell interactions are needed to cross the 
BBB, liposomes can take advantage of the endothelium 
damage, a phenomenon usually called “passive targeting”, 
in ischemic animals, leading to a higher local accumulation 
in the infarcted area.36,37
The presence of liposomes in plasma for 4 hours indicated 
that, without charge, liposomes presented higher bioavail-
ability as their signal was significantly higher compared with 
the negative and positive particles. Again, as observed in 
the brain, positive liposomes seemed to undergo a process 
of degradation, as no fluorescent signal could be detected at 
4 hours. Regarding the lack of signal in brain and plasma, 
showing the inability to cross the BBB or the poor bioavail-
ability, we considered positively charged liposomes as poor 
candidates to deliver neuroprotectant drugs into the brain and 
discarded them for further experiments in our study. Addi-
tionally, in order to examine whether neutral or negatively 
charged liposomes were the most proper delivery carriers, a 
plasma kinetics study was performed, analyzing blood lipo-
some signals from naïve animals at different time points. 
Neutral liposomes showed a more intense fluorescent signal 
both at 90 minutes and at 4 hours after being administered. 
Concordantly, some in vitro studies have demonstrated that 
neutral particles have slower opsonization rates than charged 
particles, thus preventing their phagocytosis and contributing 
to a prolonged presence in plasma.28,38
Taken as a whole, several factors seem to affect liposome 
distribution, and their surface charge is undoubtedly a deter-
minant to be taken into consideration in future therapeutic 
strategies. However, regarding the controversial literature 
previously published in which particle cationization is 
considered a way to improve the ability of particles to cross 
the BBB, we support other authors who concluded that the 
type of lipid mixture was also a key feature that can affect the 
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rate of liposome clearance.24,39 Our hypothesis is that the vast 
possibilities of liposome fabrication and the infinite drugs that 
can take advantage of its encapsulation make it really difficult 
to draw comparisons between previously published studies. 
Nevertheless, we reached the same conclusion as relevant 
systematic studies that have evaluated the pharmacokinet-
ics and biodistribution of charged PEGylated liposomes: 
negative particles exhibit strong reticuloendothelial system 
uptake; positive particles induce serum protein aggregation 
and neutral nanoparticles exhibit the least reticuloendothelial 
system interaction and the longest circulation, being the most 
suitable ones.40
The experiments on simvastatin analysis in rat brain after 
IV administration corroborated its ability to cross the BBB 
per se, as other authors previously stated.41,42 Simvastatin 
is lipophilic in nature and therefore easily diffuses across 
enterocytes’ cell membranes. Interestingly, the highest accu-
mulation was observed in infarcted hemispheres of ischemic 
animals, probably due to BBB alteration after ischemia. 
As other studies reported, with the BBB being weakened, 
systemically administered drugs can undergo enhanced 
extravasation rates in the cerebral endothelium, leading to 
increased parenchymal drug concentrations.43 Moreover, we 
could detect more simvastatin in the rat brain at 2 hours than 
at 4 hours after being administered. It is reasonable that the 
drug concentration decreases while being in the tissue, and 
it is also in agreement with Bellosta et al,44 who reported 
simvastatin elimination half-life (t
1/2
 [hours]) as 2–3 hours. 
On the other hand, it should be emphasized that simvastatin 
is an inactive hydrophobic lactone prodrug, which is com-
monly administered orally. After oral administration, it is 
described as being metabolized in vivo to several more polar 
and pharmacologically active compounds by both liver and 
plasma esterases.45–47 Given that some stroke patients suffer 
from dysphagia, we consider that parenteral statin admin-
istration would represent an improvement for their clinical 
management. This is the reason why, in our study, simvastatin 
was activated before its encapsulation and/or intravenously 
administered. Our aim was to optimize the amount of active 
simvastatin and consequently its effect. Strikingly, but 
in accordance with others, we observed that simvastatin 
metabolism is reversible and that interconversion occurs 
between the lactone (inactive) and acid (active) forms.45,48 
Consequently, we detected both forms when analyzing brain 
samples through UHPLC technique.
Remarkably, simvastatin encapsulation into liposomes 
exhibited some unexpected results. First, and contrarily to 
our hypothesis, we did not detect higher active simvastatin 
accumulation in ischemic brain region after being encapsu-
lated into liposomes. Second, sham animals presented more 
simvastatin accumulation when administered in liposomes. 
Third, liposomes seem to prevent simvastatin deactivation, 
as animals treated with encapsulated simvastatin presented 
very low levels of the inactive form.
Although our data showed similar levels of active simvas-
tatin in ischemic areas after free or encapsulated simvastatin 
administration, thus not demonstrating an enhancement in 
drug delivery occurred, we could state that liposomes do 
not impede simvastatin brain penetration. In this regard, 
variability among infarct sizes and small sample size could 
have negatively interfered with our data. At this point, we 
assume the impossibility of calculating infarct volumes as 
a clear limitation of the study. Correlation between infarct 
severity and liposome accumulation in brain would undoubt-
edly be of high interest.
On the other hand, data obtained from sham animals are 
highly remarkable. We observed that when encapsulated, 
simvastatin can be easily retained in brain tissue compared 
with free simvastatin. This could become an important 
improvement for those human patients, who receive simvas-
tatin as a preventive treatment. A higher simvastatin brain 
accumulation could enable a dose reduction and, conse-
quently, fewer possibilities to suffer secondary effects.
Finally, the effect of liposomes on altering simvastatin 
interconversion from active to inactive form would also 
represent a clear advantage. In this sense, Skottheim et al49 
reported that simvastatin lactone showed 37-fold higher 
potential to induce myotoxicity compared to its acid forms 
in a study with human skeletal muscle cells in vitro. Fur-
thermore, a remarkable increase in metabolic clearance was 
noted in another study, for all statin lactones compared with 
their acid forms.48 In accordance with these results, Romana 
et al11 reported that nanodelivery systems such as liposomes 
might solve statin problems including adverse effects on 
muscles and liver or their poor bioavailability. As we were 
able to demonstrate that liposomes can accumulate in the 
infarct area and also that simvastatin can be delivered after 
being encapsulated, further in vivo studies are needed in 
order to explore the neuroprotection effect of encapsulated 
simvastatin, as well as other attributable beneficial effects 
such as liver or muscle toxicity reduction.
Conclusion
This study confirms that liposome charge is critical to promote 
its accumulation in the brain infarct area after transient MCAO. 
Furthermore, encapsulation into neutral liposomes does not 
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hamper simvastatin from being delivered in brain tissue. Thus, 
simvastatin encapsulation might be a promising strategy to 
ensure that the drug reaches the brain, while increasing its 
bioavailability and reducing possible side effects.
Acknowledgments
We are grateful to Yolanda Fernández Amurgo and Anna 
Pujol Esclusa for their excellent technical support with ex vivo 
imaging experiments. The research leading to these results 
received funding from the European Union’s Seventh Frame-
work Program (FP7/2007-2013) under grant agreements num-
ber 201024 and number 202213 (European Stroke Network). 
Neurovascular Research Laboratory takes part in the Spanish 
stroke research network INVICTUS (RD12/0014/0005). This 
study was partially funded by projects FIS 11/0176 on stroke 
biomarkers research and EC07/90195 on increasing safety 
and efficacy of simvastatin neuroprotection. Simvastatin was 
a donation from Grupo Uriach, Barcelona, Spain.
Disclosure
MC-M is supported by a predoctoral fellowship grant (FI 
10/00508), and MH-G and AR are senior researchers in the 
Miguel Servet Program (CP12/03259 and CP09/00265), all 
three from the Instituto de Salud Carlos III of the Spanish 
Ministry of Economy. AS is supported by a predoctoral 
fellowship (2015 FI_B 00952) from the Agencia de Gestió 
d’Ajuts Universitaris i de Recerca de Catalunya. The authors 
report no other conflicts of interest in this work.
References
1. Roger VL, Go AS, Lloyd-Jones DM, et al; American Heart Association 
Statistics Committee and Stroke Statistics Subcommittee. Executive 
summary: heart disease and stroke statistics – 2012 update: a report from 
the American Heart Association. Circulation. 2012;125(1):188–197.
2. Kwiatkowski TG, Libman RB, Frankel M, et al. Effects of tissue 
plasminogen activator for acute ischemic stroke at one year. National 
Institute of Neurological Disorders and Stroke Recombinant Tissue 
Plasminogen Activator Stroke Study Group. N Engl J Med. 1999;340(23): 
1781–1787.
3. García-Bonilla L, Campos M, Giralt D, et al. Evidence for the efficacy 
of statins in animal stroke models: a meta-analysis. J Neurochem. 2012; 
122(2):233–243.
4. Campos-Martorell M, Salvador N, Monge M, et al. Brain proteomics 
identifies potential simvastatin targets in acute phase of stroke in a rat 
embolic model. J Neurochem. 2014;130(2):301–312.
5. Jonsson N, Asplund K. Does pretreatment with statins improve 
clinical outcome after stroke? A pilot case-referent study. Stroke. 2001; 
32(5):1112–1115.
6. Martí-Fàbregas J, Gomis M, Arboix A, et al. Favorable outcome of ischemic 
stroke in patients pretreated with statins. Stroke. 2004;35(5):1117–1121.
7. Balduini W, De Angelis V, Mazzoni E, Cimino M. Simvastatin protects 
against long-lasting behavioral and morphological consequences of neo-
natal hypoxic/ischemic brain injury. Stroke. 2001;32(9):2185–2191.
8. Jain MK, Ridker PM. Anti-inflammatory effects of statins: clinical evidence 
and basic mechanisms. Nat Rev Drug Discov. 2005;4(12):977–987.
 9. Wang C-Y, Liu P-Y, Liao JK. Pleiotropic effects of statin therapy: 
molecular mechanisms and clinical results. Trends Mol Med. 2008; 
14(1):37–44.
 10. Tiwari G, Tiwari R, Sriwastawa B, et al. Drug delivery systems: an 
updated review. Int J Pharm Investig. 2012;2(1):2–11.
 11. Romana B, Batger M, Prestidge CA, Colombo G, Sonvico F. Expanding 
the therapeutic potential of statins by means of nanotechnology enabled 
drug delivery systems. Curr Top Med Chem. 2014;14(9):1182–1193.
 12. Ishii T, Fukuta T, Agato Y, et al. Nanoparticles accumulate in ischemic 
core and penumbra region even when cerebral perfusion is reduced. 
Biochem Biophys Res Commun. 2013;430(4):1201–1205.
 13. Sahagun G, Moore SA, Hart MN. Permeability of neutral vs. anionic dex-
trans in cultured brain microvascular endothelium. Am J Physiol. 1990; 
259(1 pt 2):H162–H166.
 14. García-Bonilla L, Sosti V, Campos M, et al. Effects of acute post-
treatment with dipyridamole in a rat model of focal cerebral ischemia. 
Brain Res. 2011;1373:211–220.
 15. Pérez-Asensio FJ, Hurtado O, Burguete MC, et al. Inhibition of 
iNOS activity by 1400W decreases glutamate release and ameliorates 
stroke outcome after experimental ischemia. Neurobiol Dis. 2005; 
18(2):375–384.
 16. Banes-Berceli AK, Shaw S, Ma G, et al. Effect of simvastatin on high 
glucose- and angiotensin II-induced activation of the JAK/STAT 
pathway in mesangial cells. Am J Physiol Renal Physiol. 2006;291(1): 
F116–F121.
 17. Lowery A, Onishko H, Hallahan DE, Han Z. Tumor-targeted delivery of 
liposome-encapsulated doxorubicin by use of a peptide that selectively 
binds to irradiated tumors. J Control Release. 2011;72(2):181–204.
 18. Afergan E, Ben David M, Epstein H, et al. Liposomal simvastatin attenu-
ates neointimal hyperplasia in rats. AAPS J. 2010;12(2):181–187.
 19. Papagiannaros A, Kale A, Levchenko TS, Mongayt D, Hartner WC, 
Torchilin VP. Near infrared planar tumor imaging and quantifica-
tion using nanosized Alexa 750-labeled phospholipid micelles. Int 
J Nanomedicine. 2009;4:123–131.
 20. Zhang J, Rodila R, Gage E, et al. High-throughput salting-out assisted 
liquid/liquid extraction with acetonitrile for the simultaneous determina-
tion of simvastatin and simvastatin acid in human plasma with liquid 
chromatography. Anal Chim Acta. 2010;661(2):167–172.
 21. Immordino ML, Dosio F, Cattel L. Stealth liposomes: review of the 
basic science, rationale, and clinical applications, existing and potential. 
Int J Nanomedicine. 2006;1(3):297–315.
 22. Joo SP, Xie W, Xiong X, Xu B, Zhao H. Ischemic postconditioning 
protects against focal cerebral ischemia by inhibiting brain inflamma-
tion while attenuating peripheral lymphopenia in mice. Neuroscience. 
2013;243:149–157.
 23. Elbayoumi TA, Torchilin VP. Current trends in liposome research. 
Methods Mol Biol. 2010;605:1–27.
 24. Spuch C, Navarro C. Liposomes for targeted delivery of active agents 
against neurodegenerative diseases (Alzheimer’s disease and Parkin-
son’s disease). J Drug Deliv. 2011;2011:469679.
 25. Aggarwal P, Hall JB, McLeland CB, Dobrovolskaia MA, McNeil SE. 
Nanoparticle interaction with plasma proteins as it relates to particle 
biodistribution, biocompatibility and therapeutic efficacy. Adv Drug 
Deliv Rev. 2009;61(6):428–437.
 26. Kobeissy FH, Ottens AK, Zhang Z, et al. Novel differential neuropro-
teomics analysis of traumatic brain injury in rats. Mol Cell Proteomics. 
2006;5(10):1887–1898.
 27. Moghimi SM, Hunter AC, Murray JC. Long-circulating and target-
specific nanoparticles: theory to practice. Pharmacol Rev. 2001;53(2): 
283–318.
 28. Owens DE, Peppas NA. Opsonization, biodistribution, and pharmacoki-
netics of polymeric nanoparticles. Int J Pharm. 2006;307(1):93–102.
 29. Gessner A, Lieske A, Paulke B, Müller R. Influence of surface charge 
density on protein adsorption on polymeric nanoparticles: analysis 
by two-dimensional electrophoresis. Eur J Pharm Biopharm. 2002; 
54(2):165–170.
International Journal of Nanomedicine
Publish your work in this journal
Submit your manuscript here: http://www.dovepress.com/international-journal-of-nanomedicine-journal
The International Journal of Nanomedicine is an international, peer-
reviewed journal focusing on the application of nanotechnology 
in diagnostics, therapeutics, and drug delivery systems throughout 
the biomedical field. This journal is indexed on PubMed Central, 
 MedLine, CAS, SciSearch®, Current Contents®/Clinical Medicine, 
Journal Citation Reports/Science Edition, EMBase, Scopus and the 
Elsevier Bibliographic databases. The manuscript management system 
is completely online and includes a very quick and fair peer-review 
system, which is all easy to use. Visit http://www.dovepress.com/
testimonials.php to read real quotes from published authors.
International Journal of Nanomedicine 2016:11submit your manuscript | www.dovepress.com
Dovepress 
Dovepress
Dovepress
3048
campos-Martorell et al
 30. Hernández-Caselles T, Villalaín J, Gómez-Fernández JC. Influence 
of liposome charge and composition on their interaction with human 
blood serum proteins. Mol Cell Biochem. 1993;120(2):119–126.
 31. Weiss L, Zeigel R, Jung OS, Bross ID. Binding of positively charged 
particles to glutaraldehyde-fixed human erythrocytes. Exp Cell Res. 
1972;70(1):57–64.
 32. Swaroop Kumar K, Jyothi T, Nagendar S, Devipriya S, Vijaya Kumar G, 
Sudhakar Babu AM. Stability of liposomes. Pak J Pharm Sci. 1995; 
8(2):69–79.
 33. Kuroiwa T, Ting P, Martinez H, Klatzo I. The biphasic opening of the 
blood-brain barrier to proteins following temporary middle cerebral 
artery occlusion. Acta Neuropathol. 1985;68(2):122–129.
 34. Belayev L, Busto R, Zhao W, Ginsberg MD. Quantitative evaluation 
of blood-brain barrier permeability following middle cerebral artery 
occlusion in rats. Brain Res. 1996;739(1–2):88–96.
 35. Yuan F, Leunig M, Huang SK, Berk DA, Papahadjopoulos D, Jain RK. 
Microvascular permeability and interstitial penetration of sterically 
stabilized (stealth) liposomes in a human tumor xenograft. Cancer Res. 
1994;54(13):3352–3356.
 36. Schroeder A, Turjeman K, Schroeder JE, Leibergall M, Barenholz Y. 
Using liposomes to target infection and inflammation induced by for-
eign body injuries or medical implants. Expert Opin Drug Deliv. 2010; 
7(10):1175–1189.
 37. Lu W. Adsorptive-mediated brain delivery systems. Curr Pharm 
Biotechnol. 2012;13(12):2340–2348.
 38. Roser M, Fischer D, Kissel T. Surface-modified biodegradable albumin 
nano- and microspheres. II: effect of surface charges on in vitro 
phagocytosis and biodistribution in rats. Eur J Pharm Biopharm. 1998; 
46(3):255–263.
 39. Cavaletti G, Cassetti A, Canta A, et al. Cationic liposomes target sites 
of acute neuroinflammation in experimental autoimmune encephalo-
myelitis. Mol Pharm. 2009;6(5):1363–1370.
 40. Ernsting MJ, Murakami M, Roy A, Li S-D. Factors controlling the 
pharmacokinetics, biodistribution and intratumoral penetration of 
nanoparticles. J Control Release. 2013;172(3):782–794.
 41. Vuletic S, Riekse RG, Marcovina SM, Peskind ER, Hazzard WR, 
Albers JJ. Statins of different brain penetrability differentially affect CSF 
PLTP activity. Dement Geriatr Cogn Disord. 2006;22(5–6):392–398.
 42. Saheki A, Terasaki T, Tamai I, Tsuji A. In vivo and in vitro blood-brain bar-
rier transport of 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) 
reductase inhibitors. Pharm Res. 1994;11(2):305–311.
 43. Misra A, Ganesh S, Shahiwala A, Shah SP. Drug delivery to the central 
nervous system: a review. J Pharm Pharm Sci. 2003;6(2):252–273.
 44. Bellosta S, Paoletti R, Corsini A. Safety of statins: focus on clinical phar-
macokinetics and drug interactions. Circulation. 2004;109(23 suppl 1): 
III50–III57.
 45. Vickers S, Duncan CA, Chen IW, Rosegay A, Duggan DE. Metabolic 
disposition studies on simvastatin, a cholesterol-lowering prodrug. Drug 
Metab Dispos. 1990;18(2):138–145.
 46. Mauro VF. Clinical pharmacokinetics and practical applications of 
simvastatin. Clin Pharmacokinet. 1993;24(3):195–202.
 47. Lippert J, Brosch M, von Kampen O, et al. A mechanistic, model-based 
approach to safety assessment in clinical development. CPT Pharma-
cometrics Syst Pharmacol. 2012;1:e13.
 48. Fujino H, Saito T, Tsunenari Y, Kojima J, Sakaeda T. Metabolic proper-
ties of the acid and lactone forms of HMG-CoA reductase inhibitors. 
Xenobiotica. 2004;34(11–12):961–971.
 49. Skottheim IB, Gedde-Dahl A, Hejazifar S, Hoel K, Asberg A. Statin 
induced myotoxicity: the lactone forms are more potent than the 
acid forms in human skeletal muscle cells in vitro. Eur J Pharm Sci. 
2008;33(4–5):317–325.
